Danny Deadlock's 2 cents If you are a Revive shareholder I hope you are sitting down as this will be a shock to your heart !
For the second time in two weeks (the last news a partnership announced June 13th with WeedMD), Revive has released material news.
Early this morning they announced that the FDA has granted them Orphan Drug Status for their research using CBD (from the Cannabis plant) to treat Autoimmune Hepatitis.
This is early stage, but very material because it is rare to see FDA approval on a drug treatment platform (using the marijuana plant) when MJ is Federally Illegal in the United States. Similar to industry giant GW Pharma (NASDAQ), the FDA is going out of their way to help in the research and development of a treatment process based upon a schedule 1 drug. Its quite a bizarre situation.
Either way, this is VERY encouraging to see that Revive is making solid progress on the Cannabis science side. This has been my hope with the company from day one. BUT their inability to build confidence with investors and shareholders has resulted in a company that is grossly undervalued in relation to Canadian listed marijuana stock peers. Hopefully this will help.
Their corporate presentation is very well done and explains the markets they are targeting. The news from this morning is on their home page.